COYA Stock Analysis: Buy, Sell, or Hold?
COYA - Coya Therapeutics, Inc. Common Stock
$4.90
-0.06 (-1.21%)
▼
5d:
+17.22%
30d:
+2.51%
90d:
+5.38%
BUY
MODERATE Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
COYA is down 3.5% this week, but smart money is accumulating calls. Top strike: $5 2026-06-18 with 1 OI. Call ratio: 100% View Scanner →
Strength: 6.8/10
Get Alerted When COYA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called COYA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: COYA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: COYA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: COYA is currently trading at $4.90, which is considered extended relative to its 30-day fair value range of $4.15 to $4.73.
Technical Outlook: Technically, COYA is in a downtrend. Immediate support is located at $3.90, while resistance sits at $5.36.
Market Sentiment: COYA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.64 (+215.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, COYA is in a downtrend. Immediate support is located at $3.90, while resistance sits at $5.36.
Market Sentiment: COYA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.64 (+215.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.15 -
$4.73
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 215.4% below Wall St target ($15.64)
Trading Range Analysis
30-Day Trading Range
$4.15 -
$4.73
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.89
(18.2%)
Support & Resistance Levels
Support Level
$3.90
Resistance Level
$5.36
Current Trend
Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.29
Wall Street Target
$15.64
(+215.4%)
Revenue Growth (YoY)
-2.6%
Profit Margin
-266.1%
Share & Embed Analysis
Last updated: May 18, 2026 2:03 PM ET
Data refreshes hourly during market hours. Next update: 3:03 PM
Data refreshes hourly during market hours. Next update: 3:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is COYA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$90 | 50 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
